S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
Log in
NASDAQ:GRCL

Gracell Biotechnologies Stock Forecast, Price & News

$22.40
-0.45 (-1.97 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$22.18
Now: $22.40
$23.40
50-Day Range N/A
52-Week Range
$21.08
Now: $22.40
$28.88
Volume42,938 shs
Average Volume438,192 shs
Market Capitalization$1.47 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC007F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate that is in Phase I clinical trial for the treatment of B-NHL. The company's product candidates also comprise GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia; and GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase I clinical trial for the treatment of r/r B-ALL. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is based in Shanghai, China.

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1877th out of 1,926 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GRCL
CUSIPN/A
CIKN/A
Phone86 512 6262 6701
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$1.47 billion
Next Earnings DateN/A
OptionableNot Optionable
$22.40
-0.45 (-1.97 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GRCL News and Ratings via Email

Sign-up to receive the latest news and ratings for GRCL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Gracell Biotechnologies (NASDAQ:GRCL) Frequently Asked Questions

What stocks does MarketBeat like better than Gracell Biotechnologies?

Wall Street analysts have given Gracell Biotechnologies a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gracell Biotechnologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Gracell Biotechnologies' CEO?

1,448 employees have rated Gracell Biotechnologies CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Gracell Biotechnologies' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Gracell Biotechnologies' key competitors?

Who are Gracell Biotechnologies' key executives?

Gracell Biotechnologies' management team includes the following people:
  • Dr. Wei Cao, Founder, Chairman & CEO (Age 62)
  • Dr. Yili Xie M.B.A., Ph.D., Chief Financial Officer (Age 51)
  • Dr. Martina A. Sersch M.D., Ph.D., Chief Medical Officer

When did Gracell Biotechnologies IPO?

(GRCL) raised $150 million in an initial public offering on Friday, January 8th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities acted as the underwriters for the IPO.

What is Gracell Biotechnologies' stock symbol?

Gracell Biotechnologies trades on the NASDAQ under the ticker symbol "GRCL."

When does the company's quiet period expire?

Gracell Biotechnologies' quiet period expires on Wednesday, February 17th. Gracell Biotechnologies had issued 11,000,000 shares in its IPO on January 8th. The total size of the offering was $209,000,000 based on an initial share price of $19.00. During the company's quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Gracell Biotechnologies?

Shares of GRCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gracell Biotechnologies' stock price today?

One share of GRCL stock can currently be purchased for approximately $22.40.

How big of a company is Gracell Biotechnologies?

Gracell Biotechnologies has a market capitalization of $1.47 billion.

What is Gracell Biotechnologies' official website?

The official website for Gracell Biotechnologies is www.gracellbio.com.

How can I contact Gracell Biotechnologies?

The company can be reached via phone at 86 512 6262 6701.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.